Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.77 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.77 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.77 |
| ▸ | GJB2 | P29033 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450956 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL18685567 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL12908202 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067762 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL25005884 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067763 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23183598 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL21068067 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23393554 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22431206 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | AEGIS THERAPEUTICS, LLC | 2020-06-25 | — | — | US | claimed |
| US-20180325994-A1 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-11-15 | — | — | US | claimed |
| US-20170189472-A1 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | OPIANT PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | claimed |
| US-20160051624-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS LLC (US) | 2016-02-25 | — | — | US | claimed |
| US-9114069-B2 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2015-08-25 | — | — | US | claimed |
| WO-2011014797-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2011-02-03 | — | — | WO | claimed |
| US-20100068209-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | Aegis Therapeuttics LLC (US) | 2010-03-18 | — | — | US | claimed |
| US-20060046969-A1 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | claimed |
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | AEGIS THERAPEUTICS, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | NEF ROYALTY SUB LLC | 2024-01-25 | — | — | US | disclosed |
| US-20230302137-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | NEF ROYALTY SUB LLC | 2023-09-28 | — | — | US | disclosed |
| US-11744895-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | AEGIS THERAPEUTICS, LLC (US) | 2023-09-05 | — | — | US | disclosed |
| US-11717571-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | AEGIS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4169511-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | Aegis Therapeutics, LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20100160378-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS LLC (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100068209-A1 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | Aegis Therapeuttics LLC (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090163447-A1 | Compositions for Drug Administration | AEGIS THERAPEUTICS, LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090047347-A1 | Compositions for Drug Administration | AEGIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080200418-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20060046969-A1 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302137-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | LGALS8 3674/4885LGALS3 3877/4885LGALS4 3807/4885 |
| US-20200197494-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | IAPP, NGLY1, VIP | LGALS8 42/4885LGALS3 49/4885LGALS4 101/4885 |
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | ADRA2C, ADRA2A, ADRB2 | LGALS8 3674/4885LGALS3 3877/4885LGALS4 3807/4885 |
| US-11717571-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | ADRA2C, ADRA2A, ADRB2 | LGALS8 3674/4885LGALS3 3877/4885LGALS4 3807/4885 |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | LGALS8 3674/4885LGALS3 3877/4885LGALS4 3807/4885 |
| US-11744895-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | ADRA2C, ADRA2A, ADRB2 | LGALS8 3674/4885LGALS3 3877/4885LGALS4 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.